|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
- Proposed noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTPs), formerly noninvasive encapsulated papillary carcinoma, follicular variant (PTC-FV), is an indolent tumor with follicular growth and frequent RAS mutations.
|
29582677 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Application of Strict Criteria for Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Encapsulated Follicular Variant Papillary Thyroid Carcinoma: a Retrospective Study of 50 Tumors Previously Diagnosed as Follicular Variant PTC.
|
29368294 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Several of these kinases are known to be mutated or overexpressed and are involved in tumor development (discoidin domain receptor family, member 1 and 2, tropomyosin receptor kinase A (TRKA) and C, rearranged during transfection proto-oncogene [RET proto oncogene]), as well as in fibrotic diseases (e.g., DDRs).
|
29263244 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Two coding fusions (CCDC6-RET and LMO7-BRAF) were found in one tumor sample each.
|
29768105 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
FNA = fine-needle aspiration; GEC = gene expression classifier; NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC = papillary thyroid cancer; SFN = suspicious for follicular neoplasia.
|
30084677 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Among the 246 paired cases, 3 (1.22%) cases of primary tumor had identified RET rearrangement and 2 (0.81%) cases of metastases had identified RET rearrangement.
|
30429449 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Several studies have shown that, besides the neoplastic transformation of thyroid C-cells, a profound modification of tumor microenvironment has been associated to the RET FMTC/MEN2-associated oncoproteins.
|
28931560 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
After 5 months, about half of thyroid lesions escaped OIS and formed tumors that remained dependent on RET/PTC3 expression.
|
28652169 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The expression of a subset of these genes was evaluated in human MTCs and found to be associated with aggressive RET-M918T-positive tumors.
|
29142006 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Medullary thyroid carcinoma (MTC), a tumor derived from the neural crest, occurs either sporadically or as the dominant component of the type 2 multiple endocrine neoplasia (MEN) syndromes, MEN2A and MEN2B.
|
29142004 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The resistant tumor acquired a secondary mutation resulting in a serine-to-phenylalanine substitution at codon 904 in the activation loop of the RET kinase domain.
|
29434222 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
LOXO-292 Reins In RET-Driven Tumors.
|
29860229 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
BLU-667 is a potent and selective RET inhibitor that induces tumor regression in cancer models with <i>RET</i> mutations and fusions.
|
29657135 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Our analysis showed that tumor multifocality rather than size is the significant factor determining prognosis; hence, total thyroidectomy is indicated for an optimal assessment of true focality in micro-PTC.
|
28550398 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
MALAT1 expression was positively related to RET and negatively related to miR-129-5p in osteosarcoma samples and xenograft tumors.
|
30481748 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
RET-positive expression was related to poorer tumor differentiation (P < 0.05).
|
29473341 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Based on gene expression profiling classification, they can be classically assigned to either a hypoxic/angiogenic cluster (cluster 1 including tumors with mutations in SDHx, VHL and FH genes) or a kinase-signaling cluster (cluster 2 consisting in tumors related to RET, NF1, TMEM127 and MAX genes mutations, as well as most of the sporadic tumors).
|
29427052 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These findings warrant the continued development of specific antagonists targeting RET-driven neoplasms.
|
29284153 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
To date, no RET-directed targeted therapeutic has received regulatory approval for the treatment of molecularly defined populations of patients with RET-mutant or RET-rearranged solid tumours.
|
29134959 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Aberrant RET expression in a subset of cases is associated with tumor dissemination, resistance to therapies and/or poorer prognosis in multiple cancers.
|
29743166 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition.
|
29695833 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Correction to: Application of Strict Criteria for Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Encapsulated Follicular Variant Papillary Thyroid Carcinoma: a Retrospective Study of 50 Tumors Previously Diagnosed as Follicular Variant PTC.
|
29923169 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In the multivariable model, RET rearrangements were still associated with shorter OS (HR: 2.97; 95% CI, 1.25-7.07; P = 0.014), while primary tumor location, RAS and BRAF mutations and MSI status were not.
|
29538669 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In an aggressive uterine carcinosarcoma xenograft model, single-agent PTC-028 significantly delayed tumor growth and increased tumor doubling time compared with the standard carboplatin/paclitaxel therapy.
|
30026381 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
However, GFL-mediated activation of wildtype RET is an increasingly recognized mechanism promoting tumor growth and dissemination of a much broader group of cancers.
|
30666215 |
2018 |